

QlikView gave ALK-Abelló a crucial overview

“ QlikTech’s motto “seeing is believing” made very good sense in this situation. We implemented a test version in just 14 days and the results were very convincing. Rapidly, we could create an overview of our very complex clinical database and we realised right away that QlikView would be a good investment. ”

Lisbet Groes, Director of Biometrics Medical Writing, ALK-Abelló

Quickly and efficiently QlikView created the essential overview during a crucial phase, when the medico company ALK-Abelló sent their flagship product GRAZAX® to the final approval of the European medical regulatory agencies. The European Mutual Recognition Procedure for new medical products is subject to very strict deadlines and is compulsory prior to any product release on the market. In the spring of 2006 the Swedish medical regulatory agency approved the tablet based allergy vaccine GRAZAX® from ALK-Abelló for treatment of allergy towards grass pollen.



The approval was the culmination of several years of hard work to introduce the new treatment to the European market. The approval of GRAZAX® was based on results from the most comprehensive clinical development program within allergy vaccine, counting six clinical studies from a total of 1,700

patients. But ahead was the crucial European Mutual Recognition Procedure. The procedure has an indisputable deadline and the manufactures of new medical products will have to give answers to the questions of the individual countries within ten days, a deadline which must be abided. ALK-Abelló used and is still using the data management system Oracle Clinical, but with the strict and short deadlines to deliver answers ahead, a doubt rose whether in terms of resources it would work and whether it would be possible to create the needed overview in time. As 4-5 employees in the company had the competences to create overview and to retrieve data from the database, it could easily turn out being a catastrophic bottleneck. The company became aware of QlikView and the QlikTech partner Promon Denmark and that accelerated things.

“QlikTech’s motto ‘seeing is believing’ made very good sense in this situation. We implemented a test version in just 14 days and the results were very convincing. We could rapidly create an overview of our very complex clinical database and realised right away that QlikView would be a good investment. It was easy to install and we could instantly analyse data across many different parameters. In a MRP procedure, which really can be described as an eye of a needle, we have to provide answers to many different questions, as for instance whether side effects can be related to age, gender, pregnancy etc. or

Solution Overview

Company Name

ALK-Abelló

Industry

Geography

Copenhagen, Denmark

Challenges

- Need for quick and efficient overview of complex clinical database prior to MRP procedure
- Few people with the qualifications to create the needed overview and to retrieve data from the database – a bottleneck in a procedure with tight deadlines

Solution

A test version which was implemented in just 14 days convinced ALK-Abelló that QlikView was the right tool to provide them with the overview they need in the demanding MRP procedure. Today approx. 20 employees across departments and functions use QlikView. During 2008 ALK-Abelló will use QlikView on all their data. It will give them the opportunity to analyse data across many different parameters and to make all parts of the MRP procedure much more efficient than before.

Benefits

- Opportunity to make collection of data and information more efficient in a market characterised by tough competition
- Eliminates the competence bottleneck
- ROI in 1-2 month

Data Source Systems

Oracle Clinical



to a vast combination of these parameters. With QlikView any of the unit's employees can deliver this information, quickly", says Lisbet Groes, Director of Biometrics Medical Writing, ALK-Abelló.


Since the implementation of QlikView in April 2006, GRAZAX® has been approved as a subsidy eligible medical product in several European countries, and GRAZAX® has been awarded a prize as the most innovative product in 2007 by German medical doctors.

"During 2008 we will use QlikView on all our data. It will give us the opportunity to make analysis across studies and products. Today approx. 20 employees in many different functions have installed QlikView on their computers, but it is our intension to install QlikView on all

the computers of the clinical personnel, giving them direct access to a rapidly expanding data volume", says Lisbet Groes about the future with QlikView. "The clinical data is our goldmine and because of that it is a decisive competitive parameter to have easy access", she adds.

ALK-Abelló is a global leader within the development and production of drugs used for the diagnosis of allergy and for vaccines against allergy. ALK-Abelló is an expanding company, working with the latest technology within research, development and production.

ALK-Abelló's head office is located in Hørsholm north of Copenhagen, and the company will have a turnover of DKK 1.7 billion in 2007 and 1200 employees world wide.



“ It was easy to install and we were able to instantly analyse data across many different parameters. ”

Lisbet Groes, Director of Biometrics Medical Writing, ALK-Abelló.